Posts Tagged ‘Glucose Intolerance’

Glycemic Index, Insulin resistance and IGF-1

Monday, December 13th, 2010

There is a link between hair loss and Insulin resistance, glucose intolerance and IGF-1.

The studies below show that men with vertex balding had increased (higher) levels of circulating Insulin Growth Factor-1 (IGF-1) and decreased (lower) levels of circulating Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3).

J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):200-3. “Hormones and hair patterning in men: a role for insulin-like growth factor 1?”

evaluated the function of “sex steroids”, “sex hormone-binding globulin” (SHBG), and “insulin-like growth factor” (IGF-1) in determining hair-loss patterning in men. This study found that “for each 59 ng/mL increase in IGF-1, the odds of having vertex baldness doubled” and that “Testosterone, SHBG, and IGF-1 may be important in determining hair patterning in men.”

J Am Acad Dermatol. 2000 Jun;42(6):1003-7. “Vertex balding, plasma insulin-like growth factor 1, and insulin-like growth factor binding protein 3″ Found that  “Older men with vertex balding have lower circulating levels of IGFBP-3 and higher levels of IGF-1 when controlling for IGFBP-3 level.”

A link between IGF-1 and glucose intolerance / insulin resistance

Studies suggest that insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 (IGFBP-1) could be important determinants of glucose homoeostasis. The study below indicates that low IGF-1 levels are associated with the development of insulin resistance and provides “further evidence for the possible protective role of IGF-I against development of glucose intolerance.”

(more…)

Insulin Resistance Article – Archived

Thursday, August 19th, 2010

-::- Note: The below is published here for archival purposes -::-
Thanks to medscape.com for this invaluable article

Insulin Resistance

Background

Insulin resistance is a state in which a given concentration of insulin produces a less-than-expected biological effect. Insulin resistance has also been arbitrarily defined as the requirement of 200 or more units of insulin per day to attain glycemic control and to prevent ketosis.

The syndromes of insulin resistance actually make up a broad clinical spectrum, which includes obesity, glucose intolerance, diabetes, and the metabolic syndrome, as well as an extreme insulin-resistant state. Many of these disorders are associated with various endocrine, metabolic, and genetic conditions. These syndromes may also be associated with immunological diseases and may exhibit distinct phenotypic characteristics.

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
An automatic insert of some related ads:

Thanks for your patronage. Article continues below:
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

The metabolic syndrome —a state of insulin-resistance that is also known as either syndrome X or the dysmetabolic syndrome—has drawn the greatest attention because of its public health importance.

In an effort to clinically identify patients with insulin resistance, various organizations have developed diagnostic criteria. The most commonly used criteria in the United States are those of the National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATP III).

  • NCEP/ATP III criteria for the diagnosis of the metabolic syndrome include the following (diagnosis is made when 3 or more are present):
    • Waist circumference of more than 102 cm in men or more than 88 cm in women
    • Fasting triglyceride level of 150 mg/dL or higher
    • Blood pressure level of 130/85 mm Hg or higher
    • High-density lipoprotein cholesterol (HDL-C) level of less than 40 mg/dL in men or less than 50 mg/dL in women
    • Fasting glucose level of 110 mg/dL or higher (which has been changed to 100 mg/dL to reflect revised criteria for impaired fasting glucose [IFG])

    (more…)

Lancet. 2002 May 18;359(9319):1740-5. “Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study”

Wednesday, August 18th, 2010

-::- Note: The below is published here for archival purposes -::-

Lancet. 2002 May 18;359(9319):1740-5.

Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study.

Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ.

Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge, UK.

Abstract

BACKGROUND: Results of experimental and clinical studies suggest that insulin-like growth factor-I (IGF-I) and IGF binding protein-1 (IGFBP-1) could be important determinants of glucose homoeostasis. However, experimental models might also reflect compensatory and adaptive metabolic processes. We therefore prospectively examined the associations between circulating concentrations of IGF-I and IGFBP-1 and development of glucose tolerance.

METHODS: Participants in this cohort study were a random sample of 615 normoglycaemic men and women aged 45-65 years. Participants underwent oral glucose tolerance testing based on WHO definitions and criteria in 1990-92 and 1994-96. At the baseline visit, we measured serum concentrations of IGF-I and IGFBP-1, and assessed the relation between these peptides and subsequent glucose intolerance.

FINDINGS: At 4.5 years of follow-up, 51 (8%) of 615 participants developed impaired glucose tolerance or type-2 diabetes. After adjustment for correlates of IGF-I and risk factors for glucose intolerance, the odds ratio for risk of impaired glucose tolerance or type-2 diabetes for participants with IGF-I concentrations above the median (> or = 152 microg/L) compared with those with concentrations below the median (<152 microg/L) was 0.50 (0.26-0.95). Consistent with this finding, IGF-I also showed a significant inverse association with subsequent 2-h glucose concentrations, which was independent of correlates of IGF-I and risk factors for glucose tolerance (p for linear trend=0.026). We also found that this inverse association was independently modified by IGFBP-1 (p for interaction=0.011).

INTERPRETATION: These data show that circulating IGF-I and its interaction with IGFBP-1 could be important determinants of glucose homoeostasis and provide further evidence for the possible protective role of IGF-I against development of glucose intolerance.

PMID: 12049864 [PubMed - indexed for MEDLINE]

(more…)



Disclaimer: I must say this: The information presented herein is for informational purposes only. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements, making dietary changes, or before making any changes in prescribed medications.
All posts are strictly opinions meant to foster debate, education, comment, teaching, scholarship and research under the "fair use doctrine" in Section 107 of U.S. Code Title 17. No statement of fact is made and/or should be implied. Please verify all the articles on this site for yourself. The Information found here should in no way to be construed as medical advice. If You have a health issue please consult your professional medical provider. Everything here is the authors own personal opinion as reported by authors based on their personal perception and interpretation as a part of authors freedom of speech. Nothing reported here should be taken as medical advice, diagnosis or prescription; medical advice should only be taken from your health care provider. Consume the information found on this web site under your own responsibility. Please, do your own research; reach your own conclusions, and take personal responsibility and personal control of your health.